Mainz Biomed (MYNZ) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Mainz Biomed in November 2026.
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Mainz Biomed (MYNZ) Stock Forecast
Analyst price target, next 12 months
$14.00
+1558.6% vs today's $0.84
Price range over the last 12 months
Close to its 12-month low
Analysts covering Mainz Biomed have a consensus 12-month target of $14.00, above the current price of $0.84.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Mainz Biomed's stock with a target price of $14, indicating strong growth potential.
Financial Health
Mainz Biomed is generating modest revenue and cash flow, with a solid profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.